82 related articles for article (PubMed ID: 15598589)
1. Etodolac, a selective cyclo-oxygenase-2 inhibitor, enhances carboplatin-induced apoptosis of human tongue carcinoma cells by down-regulation of FAP-1 expression.
Mishima K; Nariai Y; Yoshimura Y
Oral Oncol; 2005 Jan; 41(1):77-81. PubMed ID: 15598589
[TBL] [Abstract][Full Text] [Related]
2. Carboplatin induces Fas (APO-1/CD95)-dependent apoptosis of human tongue carcinoma cells: sensitization for apoptosis by upregulation of FADD expression.
Mishima K; Nariai Y; Yoshimura Y
Int J Cancer; 2003 Jul; 105(5):593-600. PubMed ID: 12740905
[TBL] [Abstract][Full Text] [Related]
3. [Combinative effects of FAP-1 antisense oligonucleotide and carboplatin on apoptosis of ovarian cancer cell SKOV3].
Wang B; Zheng WG; Xin XY; Qi RY; Yu YC; Cao YX
Ai Zheng; 2004 Aug; 23(8):885-9. PubMed ID: 15301708
[TBL] [Abstract][Full Text] [Related]
4. Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo.
Okamoto A; Shirakawa T; Bito T; Shigemura K; Hamada K; Gotoh A; Fujisawa M; Kawabata M
Urology; 2008 Jan; 71(1):156-60. PubMed ID: 18242386
[TBL] [Abstract][Full Text] [Related]
5. FAP-1-mediated activation of NF-kappaB induces resistance of head and neck cancer to Fas-induced apoptosis.
Wieckowski E; Atarashi Y; Stanson J; Sato TA; Whiteside TL
J Cell Biochem; 2007 Jan; 100(1):16-28. PubMed ID: 16888780
[TBL] [Abstract][Full Text] [Related]
6. Survivin is a downstream target and effector of sulindac-sensitive oncogenic Stat3 signalling in head and neck cancer.
Scheper MA; Nikitakis NG; Sauk JJ
Int J Oral Maxillofac Surg; 2007 Jul; 36(7):632-9. PubMed ID: 17566705
[TBL] [Abstract][Full Text] [Related]
7. Combination of cyclooxygenase-2 inhibitors and oxaliplatin increases the growth inhibition and death in human colon cancer cells.
Lin J; Hsiao PW; Chiu TH; Chao JI
Biochem Pharmacol; 2005 Sep; 70(5):658-67. PubMed ID: 16004971
[TBL] [Abstract][Full Text] [Related]
8. Expression of receptor for advanced glycation end products during rat tongue carcinogenesis by 4-nitroquinoline 1-oxide and effect of a selective cyclooxygenase-2 inhibitor, etodolac.
Yamamoto K; Kitayama W; Denda A; Sasahira T; Kuniyasu H; Kirita T
Pathobiology; 2006; 73(6):317-24. PubMed ID: 17374970
[TBL] [Abstract][Full Text] [Related]
9. Expression of cyclooxygenase-2 in uterine endometrial cancer and anti-tumor effects of a selective COX-2 inhibitor.
Hasegawa K; Ohashi Y; Ishikawa K; Yasue A; Kato R; Achiwa Y; Nishio E; Udagawa Y
Int J Oncol; 2005 May; 26(5):1419-28. PubMed ID: 15809736
[TBL] [Abstract][Full Text] [Related]
10. Enhanced susceptibility to apoptosis of oral squamous cell carcinoma cells subjected to combined treatment with anticancer drugs and phosphatidylinositol 3-kinase inhibitors.
Iwase M; Yoshiba S; Uchid M; Takaoka S; Kurihara Y; Ito D; Hatori M; Shintani S
Int J Oncol; 2007 Nov; 31(5):1141-7. PubMed ID: 17912441
[TBL] [Abstract][Full Text] [Related]
11. Induction of apoptosis and cell cycle arrest by NS398 in oral squamous cell carcinoma cells via downregulation of E2 promoter-binding factor-1.
Du Y; Zhang S; Wang Z; Zhou W; Luan M; Yang X; Chen N
Oncol Rep; 2008 Sep; 20(3):605-11. PubMed ID: 18695912
[TBL] [Abstract][Full Text] [Related]
12. CCAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction and ubiquitin/proteasome-mediated cellular FLICE-inhibitory protein down-regulation contribute to enhancement of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by dimethyl-celecoxib in human non small-cell lung cancer cells.
Chen S; Liu X; Yue P; Schönthal AH; Khuri FR; Sun SY
Mol Pharmacol; 2007 Nov; 72(5):1269-79. PubMed ID: 17684158
[TBL] [Abstract][Full Text] [Related]
13. Suppressive effects of a selective cyclooxygenase-2 inhibitor, etodolac, on 4-nitroquinoline 1-oxide-induced rat tongue carcinogenesis.
Yamamoto K; Kitayama W; Denda A; Morisaki A; Kuniyasu H; Inoue M; Kirita T
Exp Toxicol Pathol; 2004 Dec; 56(3):145-51. PubMed ID: 15625783
[TBL] [Abstract][Full Text] [Related]
14. Arsenic trioxide induced the apoptosis of laryngeal cancer via down-regulation of survivin mRNA.
Cheng B; Yang X; Han Z; An L; Liu S
Auris Nasus Larynx; 2008 Mar; 35(1):95-101. PubMed ID: 17869043
[TBL] [Abstract][Full Text] [Related]
15. Rosiglitazone promotes tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by reactive oxygen species-mediated up-regulation of death receptor 5 and down-regulation of c-FLIP.
Kim YH; Jung EM; Lee TJ; Kim SH; Choi YH; Park JW; Park JW; Choi KS; Kwon TK
Free Radic Biol Med; 2008 Mar; 44(6):1055-68. PubMed ID: 18164688
[TBL] [Abstract][Full Text] [Related]
16. Etodolac improves 5-FU sensitivity of head and neck cancer cells through inhibition of thymidylate synthase.
Murata S; Adachi M; Kioi M; Torigoe S; Ijichi K; Hasegawa Y; Ogawa T; Bhayani MK; Lai SY; Mitsudo K; Tohnai I
Anticancer Res; 2011 Sep; 31(9):2893-8. PubMed ID: 21868535
[TBL] [Abstract][Full Text] [Related]
17. Etodolac induces apoptosis and inhibits cell adhesion to bone marrow stromal cells in human myeloma cells.
Nakamura S; Kobayashi M; Shibata K; Sahara N; Shigeno K; Shinjo K; Naito K; Hayashi H; Ohnishi K
Leuk Res; 2006 Feb; 30(2):123-35. PubMed ID: 16046235
[TBL] [Abstract][Full Text] [Related]
18. Mature miR-184 as Potential Oncogenic microRNA of Squamous Cell Carcinoma of Tongue.
Wong TS; Liu XB; Wong BY; Ng RW; Yuen AP; Wei WI
Clin Cancer Res; 2008 May; 14(9):2588-92. PubMed ID: 18451220
[TBL] [Abstract][Full Text] [Related]
19. The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Liu X; Yue P; Chen S; Hu L; Lonial S; Khuri FR; Sun SY
Cancer Res; 2007 May; 67(10):4981-8. PubMed ID: 17510429
[TBL] [Abstract][Full Text] [Related]
20. Genetic characterization of fas-associated phosphatase-1 as a putative tumor suppressor gene on chromosome 4q21.3 in hepatocellular carcinoma.
Yeh SH; Wu DC; Tsai CY; Kuo TJ; Yu WC; Chang YS; Chen CL; Chang CF; Chen DS; Chen PJ
Clin Cancer Res; 2006 Feb; 12(4):1097-108. PubMed ID: 16489062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
